Published in J Virol on November 19, 2008
Heavily isotype-dependent protective activities of human antibodies against vaccinia virus extracellular virion antigen B5. J Virol (2009) 1.69
A randomized, double-blind, dose-finding Phase II study to evaluate immunogenicity and safety of the third generation smallpox vaccine candidate IMVAMUNE. Vaccine (2009) 1.36
Complement protein C1q reduces the stoichiometric threshold for antibody-mediated neutralization of West Nile virus. Cell Host Microbe (2009) 1.27
Smallpox vaccines: targets of protective immunity. Immunol Rev (2011) 1.21
A recombinant flagellin-poxvirus fusion protein vaccine elicits complement-dependent protection against respiratory challenge with vaccinia virus in mice. Viral Immunol (2010) 1.11
Molecular smallpox vaccine delivered by alphavirus replicons elicits protective immunity in mice and non-human primates. Vaccine (2009) 1.08
Generation and characterization of a large panel of murine monoclonal antibodies against vaccinia virus. Virology (2010) 1.05
Vaccinia extracellular virions enter cells by macropinocytosis and acid-activated membrane rupture. EMBO J (2011) 1.04
Protection against lethal vaccinia virus challenge by using an attenuated matrix protein mutant vesicular stomatitis virus vaccine vector expressing poxvirus antigens. J Virol (2010) 1.04
Smallpox inhibitor of complement enzymes (SPICE): dissecting functional sites and abrogating activity. J Immunol (2009) 1.03
Combination therapy of vaccinia virus infection with human anti-H3 and anti-B5 monoclonal antibodies in a small animal model. Antivir Ther (2010) 1.02
A protein-based smallpox vaccine protects non-human primates from a lethal monkeypox virus challenge. Vaccine (2010) 0.98
The smallpox vaccine induces an early neutralizing IgM response. Vaccine (2009) 0.97
Complement modulates pathogenesis and antibody-dependent neutralization of West Nile virus infection through a C5-independent mechanism. Virology (2009) 0.93
Peek-a-boo: membrane hijacking and the pathogenesis of viral hepatitis. Trends Microbiol (2013) 0.92
Antibody against extracellular vaccinia virus (EV) protects mice through complement and Fc receptors. PLoS One (2011) 0.92
Postexposure prevention of progressive vaccinia in SCID mice treated with vaccinia immune globulin. Clin Vaccine Immunol (2010) 0.91
An epitope conserved in orthopoxvirus A13 envelope protein is the target of neutralizing and protective antibodies. Virology (2011) 0.91
Antibody inhibition of a viral type 1 interferon decoy receptor cures a viral disease by restoring interferon signaling in the liver. PLoS Pathog (2012) 0.91
The Vaccinia virus complement control protein modulates adaptive immune responses during infection. J Virol (2010) 0.88
Passive immunotherapies protect WRvFire and IHD-J-Luc vaccinia virus-infected mice from lethality by reducing viral loads in the upper respiratory tract and internal organs. J Virol (2011) 0.85
Measurement of antibody responses to Modified Vaccinia virus Ankara (MVA) and Dryvax(®) using proteome microarrays and development of recombinant protein ELISAs. Vaccine (2011) 0.84
Cloak and Dagger: Alternative Immune Evasion and Modulation Strategies of Poxviruses. Viruses (2015) 0.84
Structural and biochemical characterization of the vaccinia virus envelope protein D8 and its recognition by the antibody LA5. J Virol (2012) 0.84
Capturing the natural diversity of the human antibody response against vaccinia virus. J Virol (2010) 0.84
Protective murine and human monoclonal antibodies against eczema vaccinatum. Antivir Ther (2011) 0.83
Polyclonal antibody cocktails generated using DNA vaccine technology protect in murine models of orthopoxvirus disease. Virol J (2011) 0.83
Poxvirus complement control proteins are expressed on the cell surface through an intermolecular disulfide bridge with the viral A56 protein. J Virol (2010) 0.83
A game of numbers: the stoichiometry of antibody-mediated neutralization of flavivirus infection. Prog Mol Biol Transl Sci (2014) 0.83
Safety and Immunogenicity of Modified Vaccinia Ankara-Bavarian Nordic Smallpox Vaccine in Vaccinia-Naive and Experienced Human Immunodeficiency Virus-Infected Individuals: An Open-Label, Controlled Clinical Phase II Trial. Open Forum Infect Dis (2015) 0.82
Unusual features of vaccinia virus extracellular virion form neutralization resistance revealed in human antibody responses to the smallpox vaccine. J Virol (2012) 0.82
Epitope mapping by random peptide phage display reveals essential residues for vaccinia extracellular enveloped virion spread. Virol J (2012) 0.81
Antigen experience shapes phenotype and function of memory Th1 cells. PLoS One (2013) 0.80
Protection of rabbits and immunodeficient mice against lethal poxvirus infections by human monoclonal antibodies. PLoS One (2012) 0.80
Elucidating the role of the complement control protein in monkeypox pathogenicity. PLoS One (2012) 0.80
Ectromelia virus inhibitor of complement enzymes protects intracellular mature virus and infected cells from mouse complement. J Virol (2010) 0.80
Parainfluenza virus 5-based vaccine vectors expressing vaccinia virus (VACV) antigens provide long-term protection in mice from lethal intranasal VACV challenge. Virology (2011) 0.78
Phase 1 Study of Intravenous Oncolytic Poxvirus (vvDD) in Patients With Advanced Solid Cancers. Mol Ther (2016) 0.77
The NYCBH vaccinia virus deleted for the innate immune evasion gene, E3L, protects rabbits against lethal challenge by rabbitpox virus. Vaccine (2011) 0.77
T cell antigen discovery using soluble vaccinia proteome reveals recognition of antigens with both virion and nonvirion association. J Immunol (2014) 0.77
Serological responses in humans to the smallpox vaccine LC16m8. J Gen Virol (2011) 0.77
Disabling complement regulatory activities of vaccinia virus complement control protein reduces vaccinia virus pathogenicity. Vaccine (2011) 0.77
Adsorption of recombinant poxvirus L1-protein to aluminum hydroxide/CpG vaccine adjuvants enhances immune responses and protection of mice from vaccinia virus challenge. Vaccine (2012) 0.76
Cowpox virus induces interleukin-10 both in vitro and in vivo. Virology (2011) 0.76
The neutralizing capacity of antibodies elicited by parainfluenza virus infection of African Green Monkeys is dependent on complement. Virology (2014) 0.76
Therapeutic Vaccines and Antibodies for Treatment of Orthopoxvirus Infections. Viruses (2010) 0.76
Structural and Functional Characterization of Anti-A33 Antibodies Reveal a Potent Cross-Species Orthopoxviruses Neutralizer. PLoS Pathog (2015) 0.75
Cross-Neutralizing and Protective Human Antibody Specificities to Poxvirus Infections. Cell (2016) 0.75
Serro 2 Virus Highlights the Fundamental Genomic and Biological Features of a Natural Vaccinia Virus Infecting Humans. Viruses (2016) 0.75
Complement inhibition enables tumor delivery of LCMV glycoprotein pseudotyped viruses in the presence of antiviral antibodies. Mol Ther Oncolytics (2016) 0.75
Susceptibility of Marmosets (Callithrix jacchus) to Monkeypox Virus: A Low Dose Prospective Model for Monkeypox and Smallpox Disease. PLoS One (2015) 0.75
The mature virion of ectromelia virus, a pathogenic poxvirus, is capable of intrahepatic spread and can serve as a target for delayed therapy. J Virol (2013) 0.75
Cutting edge: long-term B cell memory in humans after smallpox vaccination. J Immunol (2003) 5.51
Antibodies, viruses and vaccines. Nat Rev Immunol (2002) 4.92
Toward an AIDS vaccine. Science (2008) 4.83
Significance of extracellular enveloped virus in the in vitro and in vivo dissemination of vaccinia. J Gen Virol (1980) 4.24
The formation and function of extracellular enveloped vaccinia virus. J Gen Virol (2002) 4.14
Studies smallpox and complications of smallpox vaccination. Pediatrics (1960) 3.87
Glycoprotein C of herpes simplex virus 1 acts as a receptor for the C3b complement component on infected cells. Nature (1984) 3.80
Extracellular vaccinia virus formation and cell-to-cell virus transmission are prevented by deletion of the gene encoding the 37,000-Dalton outer envelope protein. J Virol (1991) 3.79
Profiling the humoral immune response to infection by using proteome microarrays: high-throughput vaccine and diagnostic antigen discovery. Proc Natl Acad Sci U S A (2005) 3.59
The antiviral activity of antibodies in vitro and in vivo. Adv Immunol (2001) 3.29
The stoichiometry of antibody-mediated neutralization and enhancement of West Nile virus infection. Cell Host Microbe (2007) 3.25
Smallpox vaccine-induced antibodies are necessary and sufficient for protection against monkeypox virus. Nat Med (2005) 3.19
Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses. Proc Natl Acad Sci U S A (2003) 3.18
In a nutshell: structure and assembly of the vaccinia virion. Adv Virus Res (2006) 3.17
Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge. Proc Natl Acad Sci U S A (2004) 3.08
Variola virus immune evasion design: expression of a highly efficient inhibitor of human complement. Proc Natl Acad Sci U S A (2002) 2.95
Smallpox DNA vaccine protects nonhuman primates against lethal monkeypox. J Virol (2004) 2.72
The vaccinia virus 42-kDa envelope protein is required for the envelopment and egress of extracellular virus and for virus virulence. Virology (1993) 2.66
Deletion of the vaccinia virus B5R gene encoding a 42-kilodalton membrane glycoprotein inhibits extracellular virus envelope formation and dissemination. J Virol (1993) 2.64
Vaccinia virus encodes a secretory polypeptide structurally related to complement control proteins. Nature (1988) 2.63
Characterization of a vaccinia virus-encoded 42-kilodalton class I membrane glycoprotein component of the extracellular virus envelope. J Virol (1992) 2.60
Immunity and immunological memory following smallpox vaccination. Immunol Rev (2006) 2.57
Complement component C3 promotes T-cell priming and lung migration to control acute influenza virus infection. Nat Med (2002) 2.54
Hyperimmune vaccinal gamma globulin; source, evaluation, and use in prophylaxis and therapy. Pediatrics (1956) 2.52
Neutralization of bovine papillomavirus by antibodies to L1 and L2 capsid proteins. J Virol (1994) 2.52
Inhibition of the complement cascade by the major secretory protein of vaccinia virus. Science (1990) 2.49
Selective CD4+ T cell help for antibody responses to a large viral pathogen: deterministic linkage of specificities. Immunity (2008) 2.43
Vaccinia virus proteome: identification of proteins in vaccinia virus intracellular mature virion particles. J Virol (2006) 2.38
A tale of two clades: monkeypox viruses. J Gen Virol (2005) 2.24
Protective immunity to vaccinia virus induced by vaccination with multiple recombinant outer membrane proteins of intracellular and extracellular virions. J Virol (2004) 2.21
Vaccinia virus H3L envelope protein is a major target of neutralizing antibodies in humans and elicits protection against lethal challenge in mice. J Virol (2005) 2.18
DNA vaccination with vaccinia virus L1R and A33R genes protects mice against a lethal poxvirus challenge. Virology (2000) 2.16
Neutralizing and protective antibodies directed against vaccinia virus envelope antigens. Virology (1999) 2.15
Vaccinia virus complement-control protein prevents antibody-dependent complement-enhanced neutralization of infectivity and contributes to virulence. Proc Natl Acad Sci U S A (1992) 2.12
Protective immune responses against West Nile virus are primed by distinct complement activation pathways. J Exp Med (2006) 2.11
Proteome-wide analysis of the serological response to vaccinia and smallpox. Proteomics (2007) 2.10
Visualization of intracellular movement of vaccinia virus virions containing a green fluorescent protein-B5R membrane protein chimera. J Virol (2001) 1.98
Extracellular enveloped vaccinia virus is resistant to complement because of incorporation of host complement control proteins into its envelope. Proc Natl Acad Sci U S A (1998) 1.97
Biological characterization of recombinant vaccinia viruses in mice infected by the respiratory route. J Gen Virol (1990) 1.94
Protective T cell-independent antiviral antibody responses are dependent on complement. J Exp Med (1999) 1.79
Redundancy and plasticity of neutralizing antibody responses are cornerstone attributes of the human immune response to the smallpox vaccine. J Virol (2008) 1.77
Antibody profiling by proteome microarray reveals the immunogenicity of the attenuated smallpox vaccine modified vaccinia virus ankara is comparable to that of Dryvax. J Virol (2007) 1.77
Complement activation is required for induction of a protective antibody response against West Nile virus infection. J Virol (2005) 1.75
Medicine. The intangible value of vaccination. Science (2002) 1.75
Glycoprotein C of herpes simplex virus type 1 prevents complement-mediated cell lysis and virus neutralization. J Infect Dis (1990) 1.69
Quantification of antibody responses against multiple antigens of the two infectious forms of Vaccinia virus provides a benchmark for smallpox vaccination. Nat Med (2006) 1.64
Human monoclonal IgG isotypes differ in complement activating function at the level of C4 as well as C1q. J Exp Med (1988) 1.63
The importance of an intact complement pathway in recovery from a primary viral infection: influenza in decomplemented and in C5-deficient mice. J Immunol (1978) 1.60
Antibody-sensitive and antibody-resistant cell-to-cell spread by vaccinia virus: role of the A33R protein in antibody-resistant spread. J Gen Virol (2002) 1.59
Gene expression and cytopathic effect of vaccinia virus inactivated by psoralen and long-wave UV light. J Virol (1996) 1.58
Antibodies against the extracellular enveloped virus B5R protein are mainly responsible for the EEV neutralizing capacity of vaccinia immune globulin. Virology (2004) 1.58
The morphological and biological effects of various antisera on avian infectious bronchitis virus. J Gen Virol (1968) 1.54
Interaction of vaccinia virus complement control protein with human complement proteins: factor I-mediated degradation of C3b to iC3b1 inactivates the alternative complement pathway. J Immunol (1998) 1.49
Antibodies against vaccinia virus do not neutralize extracellular enveloped virus but prevent virus release from infected cells and comet formation. J Gen Virol (1997) 1.49
Physical and immunological characterization of a recombinant secreted form of the membrane protein encoded by the vaccinia virus L1R gene. Virology (2005) 1.49
Switch from hapten-specific immunoglobulin M to immunoglobulin D secretion in a hybrid mouse cell line. Proc Natl Acad Sci U S A (1981) 1.48
Critical role of complement and viral evasion of complement in acute, persistent, and latent gamma-herpesvirus infection. Immunity (2002) 1.45
An investigation of the therapeutic value of vaccinia-immune IgG in a mouse pneumonia model. J Gen Virol (2005) 1.45
Subunit recombinant vaccine protects against monkeypox. J Immunol (2006) 1.44
Epitope-mapping studies define two major neutralization sites on the vaccinia virus extracellular enveloped virus glycoprotein B5R. J Virol (2005) 1.44
Chimpanzee/human mAbs to vaccinia virus B5 protein neutralize vaccinia and smallpox viruses and protect mice against vaccinia virus. Proc Natl Acad Sci U S A (2006) 1.44
Mechanisms of rabies virus neutralization. Virology (1993) 1.43
A protein-based smallpox vaccine protects mice from vaccinia and ectromelia virus challenges when given as a prime and single boost. Vaccine (2006) 1.43
Association of vaccinia virus fusion regulatory proteins with the multicomponent entry/fusion complex. J Virol (2007) 1.40
Clinical efficacy of intramuscular vaccinia immune globulin: a literature review. Clin Infect Dis (2004) 1.40
Complement protein C1q inhibits antibody-dependent enhancement of flavivirus infection in an IgG subclass-specific manner. Cell Host Microbe (2007) 1.37
Humoral response to herpes simplex virus is complement-dependent. Proc Natl Acad Sci U S A (1999) 1.35
Antibody neutralization of the extracellular enveloped form of vaccinia virus. Virology (2001) 1.32
Human monkeypox infection: a family cluster in the midwestern United States. J Infect Dis (2004) 1.26
Administration to mice of a monoclonal antibody that neutralizes the intracellular mature virus form of vaccinia virus limits virus replication efficiently under prophylactic and therapeutic conditions. J Gen Virol (2002) 1.26
Golgi network targeting and plasma membrane internalization signals in vaccinia virus B5R envelope protein. J Virol (2000) 1.25
Synergistic neutralizing activities of antibodies to outer membrane proteins of the two infectious forms of vaccinia virus in the presence of complement. Virology (2004) 1.21
Immunogenicity and protection efficacy of monovalent and polyvalent poxvirus vaccines that include the D8 antigen. Virology (2006) 1.21
Structure and regulatory profile of the monkeypox inhibitor of complement: comparison to homologs in vaccinia and variola and evidence for dimer formation. J Immunol (2006) 1.21
Activity of vaccinia virus-neutralizing antibody in the sera of smallpox vaccinees. Microbes Infect (2005) 1.20
Monkeypox-induced immunity and failure of childhood smallpox vaccination to provide complete protection. Clin Vaccine Immunol (2007) 1.20
Characterization of chimpanzee/human monoclonal antibodies to vaccinia virus A33 glycoprotein and its variola virus homolog in vitro and in a vaccinia virus mouse protection model. J Virol (2007) 1.19
Effect of selective complement deficiency on the rate of neutralization of enveloped viruses by human sera. J Immunol (1977) 1.14
Prevalence of antibodies to Vaccinia virus after smallpox vaccination in Italy. J Gen Virol (2005) 1.12
In vivo anti-complementary activities of the cobra venom factors from Naja naja and Naja haje. J Immunol Methods (1991) 1.09
Role of complement in viral infections: participation of terminal complement components (C5 to C9) in recovery of mice from Sindbis virus infection. Infect Immun (1980) 1.04
Human cytomegalovirus neutralizing antibody-resistant phenotype is associated with reduced expression of glycoprotein H. J Virol (1995) 1.02
The vaccinia virus B5 protein requires A34 for efficient intracellular trafficking from the endoplasmic reticulum to the site of wrapping and incorporation into progeny virions. J Virol (2007) 1.01
Disparity between levels of in vitro neutralization of vaccinia virus by antibody to the A27 protein and protection of mice against intranasal challenge. J Virol (2008) 1.01
Antibodies to the A27 protein of vaccinia virus neutralize and protect against infection but represent a minor component of Dryvax vaccine--induced immunity. J Infect Dis (2007) 0.99
Antibody responses to vaccinia membrane proteins after smallpox vaccination. J Infect Dis (2007) 0.99
Cell surface expression of the vaccinia virus complement control protein is mediated by interaction with the viral A56 protein and protects infected cells from complement attack. J Virol (2008) 0.97
Biological activity of an intravenous preparation of human vaccinia immune globulin in mouse models of vaccinia virus infection. Antimicrob Agents Chemother (2005) 0.93
The use of hyperimmune antivaccinia gamma-globulin for the prevention and treatment of smallpox. Bull World Health Organ (1962) 0.90
Intravenous immunoglobulin products contain neutralizing antibodies to vaccinia. Vox Sang (2004) 0.87
Major neutralizing sites on vaccinia virus glycoprotein B5 are exposed differently on variola virus ortholog B6. J Virol (2007) 0.86
A one-step isolation procedure for phospholipase A2-free cobra venom factor by fast protein liquid chromatography. J Immunol Methods (1987) 0.86
Antivaccinial gamma-globulin in the control of smallpox. Lancet (1962) 0.83
Antibodies to West Nile virus: a double-edged sword. Cell Host Microbe (2007) 0.82
Structural biology: images from the surface of HIV. Nature (2006) 0.78
Bcl6 and Blimp-1 are reciprocal and antagonistic regulators of T follicular helper cell differentiation. Science (2009) 9.22
The immune epitope database and analysis resource: from vision to blueprint. PLoS Biol (2005) 7.40
ICOS receptor instructs T follicular helper cell versus effector cell differentiation via induction of the transcriptional repressor Bcl6. Immunity (2011) 5.59
Resolution of a chronic viral infection after interleukin-10 receptor blockade. J Exp Med (2006) 4.97
Human circulating PD-1+CXCR3-CXCR5+ memory Tfh cells are highly functional and correlate with broadly neutralizing HIV antibody responses. Immunity (2013) 3.72
Profiling the humoral immune response to infection by using proteome microarrays: high-throughput vaccine and diagnostic antigen discovery. Proc Natl Acad Sci U S A (2005) 3.59
STAT5 is a potent negative regulator of TFH cell differentiation. J Exp Med (2012) 3.37
A Blueprint for HIV Vaccine Discovery. Cell Host Microbe (2012) 3.27
The design and implementation of the immune epitope database and analysis resource. Immunogenetics (2005) 3.00
IL-21 and IL-6 are critical for different aspects of B cell immunity and redundantly induce optimal follicular helper CD4 T cell (Tfh) differentiation. PLoS One (2011) 2.92
Germinal center T follicular helper cell IL-4 production is dependent on signaling lymphocytic activation molecule receptor (CD150). J Immunol (2010) 2.85
In vivo regulation of Bcl6 and T follicular helper cell development. J Immunol (2010) 2.63
Immunity and immunological memory following smallpox vaccination. Immunol Rev (2006) 2.57
Selective CD4+ T cell help for antibody responses to a large viral pathogen: deterministic linkage of specificities. Immunity (2008) 2.43
Bcl6 and Maf cooperate to instruct human follicular helper CD4 T cell differentiation. J Immunol (2012) 2.34
Inadequate T follicular cell help impairs B cell immunity during HIV infection. Nat Med (2013) 2.29
Immune responses to Bacillus anthracis protective antigen in patients with bioterrorism-related cutaneous or inhalation anthrax. J Infect Dis (2004) 2.29
The receptor Ly108 functions as a SAP adaptor-dependent on-off switch for T cell help to B cells and NKT cell development. Immunity (2012) 2.19
Vaccinia virus H3L envelope protein is a major target of neutralizing antibodies in humans and elicits protection against lethal challenge in mice. J Virol (2005) 2.18
Proteome-wide analysis of the serological response to vaccinia and smallpox. Proteomics (2007) 2.10
SAP regulates T cell-mediated help for humoral immunity by a mechanism distinct from cytokine regulation. J Exp Med (2006) 1.92
Redundancy and plasticity of neutralizing antibody responses are cornerstone attributes of the human immune response to the smallpox vaccine. J Virol (2008) 1.77
Bcl6 expressing follicular helper CD4 T cells are fate committed early and have the capacity to form memory. J Immunol (2013) 1.71
Heavily isotype-dependent protective activities of human antibodies against vaccinia virus extracellular virion antigen B5. J Virol (2009) 1.69
SAP regulation of follicular helper CD4 T cell development and humoral immunity is independent of SLAM and Fyn kinase. J Immunol (2007) 1.68
Vaccinia virus-specific CD4+ T cell responses target a set of antigens largely distinct from those targeted by CD8+ T cell responses. J Immunol (2007) 1.66
Production of cattle lacking prion protein. Nat Biotechnol (2006) 1.63
Diagnosis and laparoscopic treatment of surgical diseases during pregnancy: an evidence-based review. Surg Endosc (2008) 1.60
Cutting edge: STAT1 is required for IL-6-mediated Bcl6 induction for early follicular helper cell differentiation. J Immunol (2013) 1.57
CD137 costimulatory T cell receptor engagement reverses acute disease in lupus-prone NZB x NZW F1 mice. J Clin Invest (2003) 1.52
Quantitative PCR technique for detecting lymphocytic choriomeningitis virus in vivo. J Virol Methods (2007) 1.45
Inhibition of NK cell activity by IL-17 allows vaccinia virus to induce severe skin lesions in a mouse model of eczema vaccinatum. J Exp Med (2009) 1.41
Harnessing CD4⁺ T cell responses in HIV vaccine development. Nat Med (2013) 1.39
Ly9 (CD229)-deficient mice exhibit T cell defects yet do not share several phenotypic characteristics associated with SLAM- and SAP-deficient mice. J Immunol (2006) 1.36
NKT cells prevent chronic joint inflammation after infection with Borrelia burgdorferi. Proc Natl Acad Sci U S A (2008) 1.35
OX40 drives protective vaccinia virus-specific CD8 T cells. J Immunol (2008) 1.33
Therapeutic potential of a fully human monoclonal antibody against influenza A virus M2 protein. Antiviral Res (2008) 1.30
Hypogammaglobulinemia and exacerbated CD8 T-cell-mediated immunopathology in SAP-deficient mice with chronic LCMV infection mimics human XLP disease. Blood (2006) 1.21
A lymphotoxin-IFN-beta axis essential for lymphocyte survival revealed during cytomegalovirus infection. J Immunol (2005) 1.20
Monkeypox-induced immunity and failure of childhood smallpox vaccination to provide complete protection. Clin Vaccine Immunol (2007) 1.20
Expansion of human Valpha24+ NKT cells by repeated stimulation with KRN7000. J Immunol Methods (2004) 1.19
LIGHT-HVEM signaling and the regulation of T cell-mediated immunity. Cytokine Growth Factor Rev (2003) 1.18
Dynamic regulation of Bcl6 in follicular helper CD4 T (Tfh) cells. Curr Opin Immunol (2013) 1.16
Novel potent orally active selective VEGFR-2 tyrosine kinase inhibitors: synthesis, structure-activity relationships, and antitumor activities of N-phenyl-N'-{4-(4-quinolyloxy)phenyl}ureas. J Med Chem (2005) 1.14
B cell-specific expression of B7-2 is required for follicular Th cell function in response to vaccinia virus. J Immunol (2011) 1.10
Uncovering the interplay between CD8, CD4 and antibody responses to complex pathogens. Future Microbiol (2010) 1.07
OX40 facilitates control of a persistent virus infection. PLoS Pathog (2012) 1.05
Combination therapy of vaccinia virus infection with human anti-H3 and anti-B5 monoclonal antibodies in a small animal model. Antivir Ther (2010) 1.02
Chronic lymphocytic choriomeningitis virus infection actively down-regulates CD4+ T cell responses directed against a broad range of epitopes. J Immunol (2007) 1.00
The smallpox vaccine induces an early neutralizing IgM response. Vaccine (2009) 0.97
Optimal replication of poliovirus within cells. Am Nat (2005) 0.95
An epitope conserved in orthopoxvirus A13 envelope protein is the target of neutralizing and protective antibodies. Virology (2011) 0.91
Modulation of SAP dependent T:B cell interactions as a strategy to improve vaccination. Curr Opin Virol (2013) 0.89
Structural and biochemical characterization of the vaccinia virus envelope protein D8 and its recognition by the antibody LA5. J Virol (2012) 0.84
Exogenous OX40 stimulation during lymphocytic choriomeningitis virus infection impairs follicular Th cell differentiation and diverts CD4 T cells into the effector lineage by upregulating Blimp-1. J Immunol (2013) 0.84
Protective murine and human monoclonal antibodies against eczema vaccinatum. Antivir Ther (2011) 0.83
Polyfunctional CD4+ T cell responses to a set of pathogenic arenaviruses provide broad population coverage. Immunome Res (2010) 0.83
Unusual features of vaccinia virus extracellular virion form neutralization resistance revealed in human antibody responses to the smallpox vaccine. J Virol (2012) 0.82
In-hospital outcomes and costs of surgical stabilization versus nonoperative management of severe rib fractures. J Trauma Acute Care Surg (2015) 0.81
RAC1 inhibition as a therapeutic target for gefitinib-resistant non-small-cell lung cancer. Cancer Sci (2014) 0.81
Procyanidin C1 from Cinnamomi Cortex inhibits TGF-β-induced epithelial-to-mesenchymal transition in the A549 lung cancer cell line. Int J Oncol (2013) 0.81
Protection of rabbits and immunodeficient mice against lethal poxvirus infections by human monoclonal antibodies. PLoS One (2012) 0.80
Anti-tumor effect of combining CC chemokine 22 and an anti-CD25 antibody on myeloma cells implanted subcutaneously into mice. Mol Med Rep (2011) 0.79
Therapeutics target of CXCR4 and its downstream in peritoneal carcinomatosis of gastric cancer. Front Biosci (Schol Ed) (2012) 0.79
Shane Crotty: exploring immune memory. Interview by Kira Heller. J Exp Med (2009) 0.78
Treatment of oral leukoplakia with a low-dose of beta-carotene and vitamin C supplements: a randomized controlled trial. Int J Cancer (2014) 0.78
Retroviral vector expression in TCR transgenic CD4⁺ T cells. Methods Mol Biol (2015) 0.78
T cells control the generation of nanomolar-affinity anti-glycan antibodies. J Clin Invest (2017) 0.78
Synthesis and structure-activity relationship for new series of 4-phenoxyquinoline derivatives as specific inhibitors of platelet-derived growth factor receptor tyrosine kinase. Bioorg Med Chem (2003) 0.77
Restoring immune defenses via lymphotoxin signaling: lessons from cytomegalovirus. Immunol Res (2006) 0.77
The major histocompatibility complex-restricted antigen receptor on T cells in mouse and man: identification of constant and variable peptides. 1983. J Immunol (2006) 0.76
Erratum: Activin A programs the differentiation of human TFH cells. Nat Immunol (2016) 0.75
Acute high-dose sodium selenite administration improves intestinal microcirculation without affecting cytokine release in experimental endotoxemia. J Trace Elem Med Biol (2008) 0.75
Erratum: A TRAF-like motif of the inducible costimulator ICOS controls development of germinal center TFH cells via the kinase TBK1. Nat Immunol (2016) 0.75
Erratum: Epigenetic landscapes reveal transcription factors that regulate CD8(+) T cell differentiation. Nat Immunol (2017) 0.75